This makes a lot of sense once you realise that the top 20 are the first filter level and you can boil it down to a few possibilities.

I should point out that many Biotech C suite folks are ex BP so should understand the dynamic from the inside and if you’re in a certain niche (say epilepsy) the biggest player may reside outside the top 20 (but will still think like BP).